Drug Device Combination Products Market - Global Forecast To 2030
商品番号 : SMB-78980
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 326 |
| 図表数 | 363 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、医薬品・医療機器複合製品市場を製品タイプ、用途、地域別に分析しています。また、市場成長に影響を与える要因（推進要因、制約要因、機会、課題など）を分析するとともに、市場リーダーの競争環境の詳細も提供しています。さらに、ミクロ市場を個々の成長傾向に基づいて分析し、5つの主要地域（および各地域に属する国）における市場セグメントの収益予測も提供しています。
The global drug device combination products market is projected to reach USD 379.17 billion by 2030 from USD 243.02 billion in 2025, at a CAGR of 9.3% during the forecast period.
世界の医薬品・医療機器複合製品市場は、予測期間中に9.3%のCAGRで成長し、2025年の2,430.2億米ドルから2030年には3,791.7億米ドルに達すると予測されています。
The rapid expansion of the geriatric demographic, coupled with a notable increase in patients suffering from chronic conditions such as diabetes and cardiovascular diseases, is projected to drive the market for drug-device combination products significantly. Additionally, the steady rise in self-administration practices and a heightened emphasis on patient-centric design and adherence to treatment regimens are expected to further propel market growth. Technological advancements in drug-device combination products, the introduction of innovative products, and favorable reimbursement frameworks, along with supportive government policies, are all anticipated to enhance market dynamics. Furthermore, strategic investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of these combination products will likely contribute significantly to market expansion.
高齢化の急速な拡大に加え、糖尿病や心血管疾患といった慢性疾患を患う患者数の顕著な増加が、医薬品・医療機器複合製品市場を大きく牽引すると予測されています。さらに、自己投与の着実な増加、患者中心の設計と治療計画の遵守への重視の高まりも、市場の成長をさらに促進すると予想されます。医薬品・医療機器複合製品における技術の進歩、革新的な製品の導入、有利な償還制度、そして政府の支援政策は、いずれも市場のダイナミクスを強化すると予想されます。さらに、医療インフラへの戦略的投資や、これらの複合製品のアクセス性と価格向上に向けた取り組みも、市場拡大に大きく貢献すると考えられます。
The injectable drug delivery devices segment is expected to grow at the highest CAGR during the forecast period.
In the realm of drug-device combination products, injectable drug delivery systems command the largest market share and are experiencing accelerated growth. This trend is predominantly due to their capacity for rapid, targeted administration of complex biologics and other therapies that are unsuitable for oral delivery routes. The escalating prevalence of chronic diseases, such as diabetes and cancer, is a primary driver of demand in this sector. Additionally, the industry is witnessing a paradigm shift towards self-administration facilitated by user-centered designs, including autoinjectors and pen injectors. Continuous innovation in device technology is enhancing patient comfort, safety, and adherence, further propelling market growth.
The autoinjectors subsegment of the injectable drug delivery devices segment captured the largest market share in 2024.
The injectable drug delivery devices can be subcategorized into prefilled syringes, pen injectors, autoinjectors, needle-free injectors, and wearable injectors. Among these, autoinjectors have experienced a pronounced growth trajectory in the market due to their user-friendly design, convenience, and capability to administer accurate doses of medication. These features make autoinjectors particularly suitable for patients with chronic conditions such as diabetes and multiple sclerosis. The architecture of autoinjectors facilitates self-administration, which enhances patient adherence to treatment regimens and minimizes the necessity for frequent visits to healthcare facilities. Given the rising emphasis on home-based care and patient-centric therapeutic solutions, the market for autoinjectors is poised for significant expansion.
North America accounted for the largest market share in 2024.
The global market for drug-device combination products is categorized into five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Currently, North America dominates this market due to its substantial burden of chronic diseases, particularly diabetes, which enlarges the patient demographic that relies on these combination products. The region’s market growth is further bolstered by the presence of several major industry players and supportive reimbursement policies that facilitate access to innovative therapies. Meanwhile, the Asia Pacific region is projected to experience the highest CAGR during the forecast period, indicating a burgeoning demand and potential for expansion in this sector.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25%
- By Designation: C-level–30%, Director-level–23%, and Other Designations–47%
- By Region: North America–35%, Europe–20%, Asia Pacific–25%, Latin America–13%, and Middle East & Africa–7%
The major players operating in the drug device combination products market are Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Stryker (US), B. Braun SE (Germany), Terumo Corporation (Japan) and Kaleo, Inc.(US).
Research Coverage
This report studies the drug device combination products market based on product type, application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will allow both established companies and new or smaller firms to understand market trends, helping them to increase their market share. Firms that purchase the report can use one or a combination of the strategies mentioned below to enhance their market presence.
This report provides insights on the following pointers:
- Analysis of Key divers (increasing prevalence of chronic disease, technological advancements in drug device combination products, new product launches & high R&D investment), restraints (stringent regulatory requirement), opportunities (growth in emerging economies, growing adoption of drug device combination products), challenge (lack of training and awareness, and product malfunction & wastage)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the drug device combination products market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the drug device combination products market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the drug device combination products market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key sources of secondary data 34
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 35
2.1.2.1 Key objectives of primary research 36
2.1.2.2 Key industry insights 37
2.1.2.3 Breakdown of primaries 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 39
2.2.2 MNM REPOSITORY ANALYSIS 41
2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS 41
2.2.4 TOP-DOWN APPROACH 41
2.3 MARKET GROWTH RATE PROJECTION 42
2.4 DATA TRIANGULATION 43
2.5 STUDY ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 44
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 DRUG DEVICE COMBINATION PRODUCTS MARKET OVERVIEW 51
4.2 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION AND COUNTRY 52
4.3 DRUG DEVICE COMBINATION PRODUCTS MARKET: GEOGRAPHIC
GROWTH OPPORTUNITIES 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Rising prevalence of chronic diseases 55
5.2.1.2 Growing adoption of biologics and vaccines 57
5.2.1.3 High R&D investments from government organizations and
private bodies 58
5.2.1.4 Shift toward personalized medicines and patient-centric care 59
5.2.1.5 Rising popularity of self-administered medicines 59
5.2.2 RESTRAINTS 59
5.2.2.1 Stringent regulatory policies and compliance hurdles 59
5.2.2.2 Focus on alternative drug delivery methods 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Increased preference for minimally invasive products 60
5.2.3.2 High growth potential in emerging economies 61
5.2.3.3 Growing adoption of drug device combination products and expanding biologics market 61
5.2.4 CHALLENGES 62
5.2.4.1 Heavy financial impact of drug wastage and device malfunction 62
5.2.4.2 Lack of standardized reimbursement policies 62
5.2.4.3 Limited training and education for healthcare professionals 63
5.2.4.4 Lack of medical specialists and surgeons 63
5.3 INDUSTRY TRENDS 63
5.3.1 RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND
HOME CARE SETTINGS 63
5.3.2 INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH
SMART CONNECTED DEVICES 64
5.4 TECHNOLOGY ANALYSIS 64
5.4.1 KEY TECHNOLOGIES 64
5.4.1.1 Wearable technologies 64
5.4.1.2 Drug-eluting technologies 65
5.4.2 COMPLEMENTARY TECHNOLOGIES 65
5.4.2.1 Connected health and digital technologies 65
5.4.3 ADJACENT TECHNOLOGIES 66
5.4.3.1 Advanced materials and biopolymers 66
5.5 PORTER’S FIVE FORCES ANALYSIS 67
5.5.1 THREAT OF NEW ENTRANTS 68
5.5.2 THREAT OF SUBSTITUTES 68
5.5.3 BARGAINING POWER OF SUPPLIERS 68
5.5.4 BARGAINING POWER OF BUYERS 69
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.6 KEY STAKEHOLDERS & BUYING CRITERIA 69
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
5.6.2 KEY BUYING CRITERIA 70
5.7 REGULATORY ANALYSIS 71
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 71
5.7.2 REGULATORY FRAMEWORK 74
5.7.2.1 North America 74
5.7.2.1.1 US 74
5.7.2.1.2 Canada 76
5.7.2.2 Europe 77
5.7.2.3 Asia Pacific 78
5.7.2.3.1 India 78
5.7.2.3.2 China 78
5.7.2.3.3 Japan 78
5.7.2.4 Latin America 79
5.7.2.5 Middle East & Africa 79
5.8 PATENT ANALYSIS 80
5.8.1 KEY PATENTS GRANTED 81
5.9 TRADE ANALYSIS 82
5.9.1 TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431),
2019–2023 82
5.9.1.1 Import data for HS Code 300431 82
5.9.1.2 Export data for HS Code 300431 83
5.9.2 TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019–2023 83
5.9.2.1 Import data for HS Code 300431 84
5.9.2.2 Export data for HS Code 300431 85
5.10 PRICING ANALYSIS 85
5.10.1 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS,
BY KEY PLAYER, 2024 86
5.10.2 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022–2024 87
5.10.3 AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022–2024 87
5.10.3.1 Average selling price trend for pen injectors, 2022–2024 88
5.10.3.2 Average selling price trend for inhalers, 2022–2024 88
5.10.3.3 Average selling price trend for drug-eluting stents, 2022–2024 88
5.11 VALUE CHAIN ANALYSIS 89
5.12 KEY CONFERENCES & EVENTS, 2025–2026 90
5.13 UNMET NEEDS/END-USER EXPECTATIONS 91
5.14 ADJACENT MARKET ANALYSIS 92
5.15 ECOSYSTEM ANALYSIS 92
5.15.1 ROLE IN ECOSYSTEM 93
5.16 CASE STUDY ANALYSIS 94
5.16.1 MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY 94
5.16.2 DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO
TRACK LUNG FUNCTION 94
5.16.3 ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES 95
5.17 SUPPLY CHAIN ANALYSIS 95
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
5.19 INVESTMENT & FUNDING SCENARIO 98
5.20 REIMBURSEMENT SCENARIO ANALYSIS 98
5.21 CLINICAL PIPELINE ANALYSIS 99
5.22 IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET 102
5.23 IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET 103
5.23.1 KEY TARIFF RATES 104
5.23.2 PRICE IMPACT ANALYSIS 105
5.23.3 IMPACT ON COUNTRY/REGION 106
5.23.3.1 North America 106
5.23.3.1.1 US 106
5.23.3.2 Europe 106
5.23.3.3 Asia Pacific 106
5.23.4 IMPACT ON END-USE INDUSTRIES 107
5.23.4.1 Hospitals & clinics 107
5.23.4.2 Ambulatory surgery centers 107
5.23.4.3 Long-term care facilities 107
5.23.4.4 Home care settings 107
6 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE 108
6.1 INTRODUCTION 109
6.2 INJECTABLE DRUG DELIVERY DEVICES 109
6.2.1 PREFILLED SYRINGES 112
6.2.1.1 Need to eliminate dosing mistakes and improve patient compliance to drive segment 112
6.2.2 PEN INJECTORS 113
6.2.2.1 Ease of self-administration and improved dosage accuracy
to fuel adoption 113
6.2.3 AUTOINJECTORS 116
6.2.3.1 Ease of use and better patient experience to aid adoption in emergency medical conditions 116
6.2.4 WEARABLE INJECTORS 118
6.2.4.1 Rising popularity of embedded wireless devices to propel
market growth 118
6.2.5 NEEDLE-FREE INJECTORS 120
6.2.5.1 Reduced risk of needlestick injury to fuel market adoption 120
6.3 DRUG-ELUTING STENTS 122
6.3.1 LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH 122
6.4 INHALERS 124
6.4.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE 124
6.5 INFUSION PUMPS 126
6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS 126
6.6 TRANSDERMAL PATCHES 128
6.6.1 RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH 128
6.7 DRUG-COATED BALLOONS 130
6.7.1 ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET 130
6.8 OTHER PRODUCT TYPES 131
7 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION 133
7.1 INTRODUCTION 134
7.2 DIABETES MANAGEMENT 134
7.2.1 HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH 134
7.3 RESPIRATORY DISEASES 137
7.3.1 RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS 137
7.4 OPTHALMOLOGY 139
7.4.1 RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH 139
7.5 AUTOIMMUNE DISEASES 140
7.5.1 NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO
SPUR MARKET GROWTH 140
7.6 ONCOLOGY 142
7.6.1 DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT 142
7.7 INFECTIOUS DISEASES 144
7.7.1 IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH 144
7.8 CARDIOVASCULAR DISEASES 145
7.8.1 INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH 145
7.9 OBESITY MANAGEMENT 147
7.9.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH 147
7.10 PAIN MANAGEMENT 149
7.10.1 BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES 149
7.11 OTHER APPLICATIONS 150
8 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER 152
8.1 INTRODUCTION 153
8.2 HOSPITALS & CLINICS 153
8.2.1 ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH 153
8.3 AMBULATORY SURGERY CENTERS 155
8.3.1 NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH 155
8.4 LONG-TERM CARE FACILITIES 157
8.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET 157
8.5 HOME CARE SETTINGS 159
8.5.1 INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH 159
8.6 OTHER END USERS 161
9 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION 163
9.1 INTRODUCTION 164
9.2 NORTH AMERICA 165
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165
9.2.2 US 169
9.2.2.1 US to dominate North American drug device combination products market during forecast period 169
9.2.3 CANADA 172
9.2.3.1 Regulatory modernization and strategic government investments to augment market growth 172
9.3 EUROPE 175
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175
9.3.2 GERMANY 178
9.3.2.1 Technological advancements and strong R&D infrastructure to propel market growth 178
9.3.3 UK 181
9.3.3.1 Strong emphasis on personalized and value-based healthcare to aid market growth 181
9.3.4 FRANCE 184
9.3.4.1 Strong healthcare infrastructure and high investments in biopharmaceutical innovation to boost market growth 184
9.3.5 ITALY 187
9.3.5.1 Focus on pharmaceutical-meditech convergence and healthcare modernization to drive market 187
9.3.6 SPAIN 190
9.3.6.1 Increasing geriatric population and growing focus on home-based treatment to propel market growth 190
9.3.7 REST OF EUROPE 193
9.4 ASIA PACIFIC 195
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 195
9.4.2 CHINA 199
9.4.2.1 Favorable government policies and increased healthcare spending to support market growth 199
9.4.3 JAPAN 202
9.4.3.1 Advanced healthcare systems and universal reimbursement policies to spur market growth 202
9.4.4 INDIA 205
9.4.4.1 Growing focus on digital health integration and booming biosimilars sector to drive market 205
9.4.5 SOUTH KOREA 208
9.4.5.1 Robust R&D infrastructure and enhanced focus on government-industry collaborations to aid market growth 208
9.4.6 AUSTRALIA 211
9.4.6.1 Rising healthcare investments by government and private organizations to boost market growth 211
9.4.7 REST OF ASIA PACIFIC 214
9.5 LATIN AMERICA 216
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 216
9.5.2 BRAZIL 219
9.5.2.1 Presence of universal healthcare system and high geriatric population to drive market 219
9.5.3 MEXICO 221
9.5.3.1 Focus on nearshoring and improvement in healthcare sector to
drive market 221
9.5.4 REST OF LATIN AMERICA 224
9.6 MIDDLE EAST & AFRICA 226
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 226
9.6.2 GCC COUNTRIES 229
9.6.2.1 Kingdom of Saudi Arabia 232
9.6.2.1.1 Developed medical tourism and favorable government initiatives to support market growth 232
9.6.2.2 UAE 235
9.6.2.2.1 Increased prevalence of diabetes and focus on innovative patient-centric care to drive market 235
9.6.2.3 Rest of GCC countries 237
9.6.3 REST OF MIDDLE EAST & AFRICA 239
10 COMPETITIVE LANDSCAPE 242
10.1 INTRODUCTION 242
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 242
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET 242
10.3 REVENUE ANALYSIS, 2020–2024 244
10.4 MARKET SHARE ANALYSIS, 2024 245
10.4.1 RANKING OF KEY MARKET PLAYERS 250
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 251
10.5.1 STARS 251
10.5.2 EMERGING LEADERS 251
10.5.3 PERVASIVE PLAYERS 251
10.5.4 PARTICIPANTS 251
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 253
10.5.5.1 Company footprint 253
10.5.5.2 Region footprint 254
10.5.5.3 Product type footprint 255
10.5.5.4 Application footprint 256
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 257
10.6.1 PROGRESSIVE COMPANIES 257
10.6.2 RESPONSIVE COMPANIES 257
10.6.3 DYNAMIC COMPANIES 257
10.6.4 STARTING BLOCKS 257
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 259
10.6.5.1 Detailed list of key startups/SME players 259
10.6.5.2 Competitive benchmarking of key startups/SME players 259
10.7 COMPANY VALUATION & FINANCIAL METRICS 260
10.7.1 FINANCIAL METRICS 260
10.7.2 COMPANY VALUATION 260
10.8 BRAND/PRODUCT COMPARISON 261
10.9 COMPETITIVE SCENARIO 261
10.9.1 PRODUCT LAUNCHES AND APPROVALS 261
10.9.2 DEALS 262
10.9.3 EXPANSIONS 263
10.9.4 OTHER DEVELOPMENTS 265
11 COMPANY PROFILES 266
11.1 KEY PLAYERS 266
11.1.1 ABBOTT 266
11.1.1.1 Business overview 266
11.1.1.2 Products offered 267
11.1.1.3 Recent developments 268
11.1.1.3.1 Product launches and approvals 268
11.1.1.3.2 Deals 269
11.1.1.4 MnM view 269
11.1.1.4.1 Right to win 269
11.1.1.4.2 Strategic choices 269
11.1.1.4.3 Weaknesses & competitive threats 269
11.1.2 ELI LILLY AND COMPANY 270
11.1.2.1 Business overview 270
11.1.2.2 Products offered 271
11.1.2.3 Recent developments 273
11.1.2.3.1 Product approvals 273
11.1.2.3.2 Deals 274
11.1.2.3.3 Expansions 275
11.1.2.3.4 Other developments 276
11.1.2.4 MnM view 276
11.1.2.4.1 Right to win 276
11.1.2.4.2 Strategic choices 276
11.1.2.4.3 Weaknesses & competitive threats 277
11.1.3 MEDTRONIC 278
11.1.3.1 Business overview 278
11.1.3.2 Products offered 279
11.1.3.3 Recent developments 281
11.1.3.3.1 Product launches and approvals 281
11.1.3.3.2 Deals 282
11.1.3.4 MnM view 282
11.1.3.4.1 Right to win 282
11.1.3.4.2 Strategic choices 282
11.1.3.4.3 Weaknesses & competitive threats 283
11.1.4 NOVO NORDISK A/S 284
11.1.4.1 Business overview 284
11.1.4.2 Products offered 285
11.1.4.3 Recent developments 286
11.1.4.3.1 Product launches and approvals 286
11.1.4.3.2 Deals 287
11.1.4.3.3 Expansions 288
11.1.4.4 MnM view 289
11.1.4.4.1 Right to win 289
11.1.4.4.2 Strategic choices 289
11.1.4.4.3 Weaknesses & competitive threats 290
11.1.5 NOVARTIS AG 291
11.1.5.1 Business overview 291
11.1.5.2 Products offered 292
11.1.5.3 Recent developments 294
11.1.5.3.1 Product approvals 294
11.1.5.3.2 Deals 294
11.1.5.3.3 Expansions 295
11.1.5.4 MnM view 295
11.1.5.4.1 Right to win 295
11.1.5.4.2 Strategic choices 295
11.1.5.4.3 Weaknesses & competitive threats 296
11.1.6 SANOFI 297
11.1.6.1 Business overview 297
11.1.6.2 Products offered 298
11.1.6.3 Recent developments 299
11.1.6.3.1 Product approvals 299
11.1.6.3.2 Deals 300
11.1.6.3.3 Other developments 301
11.1.7 BOSTON SCIENTIFIC CORPORATION 302
11.1.7.1 Business overview 302
11.1.7.2 Products offered 303
11.1.7.3 Recent developments 305
11.1.7.3.1 Product approvals 305
11.1.7.3.2 Deals 305
11.1.8 BECTON, DICKINSON AND COMPANY 306
11.1.8.1 Business overview 306
11.1.8.2 Products offered 307
11.1.8.3 Recent developments 308
11.1.8.3.1 Deals 308
11.1.8.3.2 Other developments 308
11.1.9 MERCK KGAA 309
11.1.9.1 Business overview 309
11.1.9.2 Products offered 310
11.1.9.3 Recent developments 311
11.1.9.3.1 Deals 311
11.1.10 ABBVIE INC. 312
11.1.10.1 Business overview 312
11.1.10.2 Products offered 313
11.1.10.3 Recent developments 314
11.1.10.3.1 Product approvals 314
11.1.10.3.2 Deals 315
11.1.10.3.3 Expansions 315
11.1.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 316
11.1.11.1 Business overview 316
11.1.11.2 Products offered 317
11.1.11.3 Recent developments 318
11.1.11.3.1 Product approvals 318
11.1.11.3.2 Other developments 318
11.1.12 STRYKER 319
11.1.12.1 Business overview 319
11.1.12.2 Products offered 320
11.1.13 B. BRAUN SE 321
11.1.13.1 Business overview 321
11.1.13.2 Products offered 322
11.1.14 TERUMO CORPORATION 323
11.1.14.1 Business overview 323
11.1.14.2 Products offered 324
11.1.14.3 Recent developments 325
11.1.14.3.1 Product launches and approvals 325
11.2 OTHER PLAYERS 326
11.2.1 TANDEM DIABETES CARE, INC. 326
11.2.2 CEQUR SIMPLICITY 326
11.2.3 INTARCIA THERAPEUTICS, INC. 327
11.2.4 HALOZYME, INC. 327
11.2.5 KALEO, INC. 328
11.2.6 LEAD CHEMICAL CO., LTD. 329
11.2.7 PURDUE PHARMA L.P. 329
11.2.8 ALVOGEN 330
11.2.9 EVOLUTIS 330
11.2.10 MUNDIPHARMA INTERNATIONAL LIMITED 331
11.2.11 SPARSHA PHARMA INTERNATIONAL PVT. LTD. 332
11.2.12 SUPERNUS PHARMACEUTICALS, INC. 333
11.2.13 ALCON INC. 334
12 APPENDIX 335
12.1 DISCUSSION GUIDE 335
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 342
12.3 CUSTOMIZATION OPTIONS 344
12.4 RELATED REPORTS 344
12.5 AUTHOR DETAILS 345
LIST OF TABLES
TABLE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: INCLUSIONS & EXCLUSIONS 31
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32
TABLE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: STUDY ASSUMPTIONS 44
TABLE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: RISK ANALYSIS 45
TABLE 5 DIABETES POPULATION WORLDWIDE, 2024 VS. 2050 (MILLION) 55
TABLE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES 68
TABLE 7 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS 70
TABLE 8 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS 70
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 71
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 14 US: CLASSIFICATION AND APPROVAL PATHWAYS 75
TABLE 15 US: CLASSIFICATION OF MEDICAL EQUIPMENT 75
TABLE 16 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75
TABLE 17 CANADA: CLASSIFICATION OF DRUG DEVICE COMBINATION PRODUCTS 76
TABLE 18 CANADA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77
TABLE 19 EUROPE: EUROPEAN REGULATORY FRAMEWORK FOR
DRUG DEVICE COMBINATION PRODUCTS 77
TABLE 20 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77
TABLE 21 CHINA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78
TABLE 22 JAPAN: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 79
TABLE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PATENTS GRANTED, JANUARY 2022−APRIL 2025 81
TABLE 24 IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 82
TABLE 25 EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 83
TABLE 26 IMPORTS DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 84
TABLE 27 EXPORT DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 85
TABLE 28 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS,
BY KEY PLAYER, 2024 86
TABLE 29 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DEVICE DELIVERY DEVICES, BY KEY PLAYER, 2022–2024 87
TABLE 30 AVERAGE SELLING PRICE TREND FOR PEN INJECTORS, BY REGION, 2022–2024 88
TABLE 31 AVERAGE SELLING PRICE TREND FOR INHALERS, BY REGION, 2022–2024 88
TABLE 32 AVERAGE SELLING PRICE TREND FOR DRUG-ELUTING STENTS,
BY REGION, 2022–2024 88
TABLE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 90
TABLE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: ROLE IN ECOSYSTEM 93
TABLE 35 CASE STUDY 1: MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY 94
TABLE 36 CASE STUDY 2: DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO
TRACK LUNG FUNCTION 94
TABLE 37 CASE STUDY 3: ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO
IMPROVE THERAPEUTIC OUTCOMES 95
TABLE 38 DRUG DEVICE COMBINATION PRODUCTS MARKET: REIMBURSEMENT
SCENARIO ANALYSIS 98
TABLE 39 DRUG DEVICE COMBINATION PRODUCTS MARKET: CLINICAL PIPELINE ANALYSIS (AS OF MARCH 2025) 99
TABLE 40 US-ADJUSTED RECIPROCAL TARIFF RATES 104
TABLE 41 KEY PRODUCT-RELATED TARIFF FOR DRUG DEVICE PRODUCTS 105
TABLE 42 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE,
2023–2030 (USD BILLION) 109
TABLE 43 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 110
TABLE 44 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY COUNTRY, 2023–2030 (USD BILLION) 111
TABLE 45 LIST OF KEY PREFILLED SYRINGES AVAILABLE IN MARKET 112
TABLE 46 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 113
TABLE 47 LAUNCH OF KEY GLP-1-RELATED INJECTABLES BY MAJOR PHARMACEUTICAL COMPANIES, 2010–2024 114
TABLE 48 LIST OF KEY PEN INJECTORS AVAILABLE IN MARKET 114
TABLE 49 PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 115
TABLE 50 LIST OF KEY AUTOINJECTORS AVAILABLE IN MARKET 116
TABLE 51 AUTOINJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION) 117
TABLE 52 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS
(20–79 YEARS), 2021 VS. 2045 (MILLION) 118
TABLE 53 LIST OF KEY WEREABLE INJECTORS AVAILABLE IN MARKET 119
TABLE 54 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 119
TABLE 55 LIST OF KEY NEEDLE-FREE INJECTORS AVAILABLE IN MARKET 120
TABLE 56 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION) 121
TABLE 57 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-ELUTING STENTS,
BY COUNTRY, 2023–2030 (USD BILLION) 123
TABLE 58 LIST OF KEY INHALERS AVAILABLE IN MARKET 124
TABLE 59 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INHALERS, BY COUNTRY, 2023–2030 (USD BILLION) 125
TABLE 60 LIST OF KEY INFUSION PUMPS AVAILABLE IN MARKET 126
TABLE 61 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFUSION PUMPS,
BY COUNTRY, 2023–2030 (USD BILLION) 127
TABLE 62 LIST OF KEY TRANSDERMAL PATCHES AVAILABLE IN MARKET 128
TABLE 63 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2023–2030 (USD BILLION) 129
TABLE 64 LIST OF KEY DRUG-COATED BALLOONS AVAILABLE IN MARKET 130
TABLE 65 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-COATED BALLOONS, BY COUNTRY, 2023–2030 (USD BILLION) 131
TABLE 66 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER PRODUCT TYPES, BY COUNTRY, 2023–2030 (USD BILLION) 132
TABLE 67 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 134
TABLE 68 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION) 136
TABLE 69 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 138
TABLE 70 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2023–2030 (USD BILLION) 140
TABLE 71 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 141
TABLE 72 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 143
TABLE 73 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR
INFECTIOUS DISEASES 144
TABLE 74 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD BILLION) 145
TABLE 75 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 146
TABLE 76 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR
OBESITY MANAGEMENT 147
TABLE 77 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OBESITY MANAGEMENT,
BY COUNTRY, 2023–2030 (USD BILLION) 148
TABLE 78 KEY TRANSDERMAL PATCHES AVAILABLE FOR PAIN MANAGEMENT 149
TABLE 79 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PAIN MANAGEMENT,
BY COUNTRY, 2023–2030 (USD BILLION) 150
TABLE 80 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD BILLION) 151
TABLE 81 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 153
TABLE 82 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2030 (USD BILLION) 154
TABLE 83 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION) 156
TABLE 84 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD BILLION) 158
TABLE 85 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2023–2030 (USD BILLION) 160
TABLE 86 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD BILLION) 162
TABLE 87 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION,
2023–2030 (USD BILLION) 164
TABLE 88 TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 164
TABLE 89 DRUG-ELUTING STENTS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 165
TABLE 90 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 166
TABLE 91 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 167
TABLE 92 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 167
TABLE 93 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 168
TABLE 94 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 168
TABLE 95 US: KEY MACROINDICATORS 169
TABLE 96 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE,
2023–2030 (USD BILLION) 170
TABLE 97 US: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 170
TABLE 98 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 171
TABLE 99 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 171
TABLE 100 CANADA: KEY MACROINDICATORS 172
TABLE 101 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 173
TABLE 102 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 173
TABLE 103 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 174
TABLE 104 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 174
TABLE 105 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 175
TABLE 106 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 176
TABLE 107 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 176
TABLE 108 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 177
TABLE 109 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 177
TABLE 110 GERMANY: KEY MACROINDICATORS 178
TABLE 111 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 179
TABLE 112 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 179
TABLE 113 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 180
TABLE 114 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 180
TABLE 115 UK: KEY MACROINDICATORS 181
TABLE 116 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE,
2023–2030 (USD BILLION) 182
TABLE 117 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 182
TABLE 118 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 183
TABLE 119 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 183
TABLE 120 FRANCE: KEY MACROINDICATORS 184
TABLE 121 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 185
TABLE 122 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 185
TABLE 123 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 186
TABLE 124 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 186
TABLE 125 ITALY: KEY MACROINDICATORS 187
TABLE 126 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 188
TABLE 127 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 188
TABLE 128 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 189
TABLE 129 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 189
TABLE 130 SPAIN: KEY MACROINDICATORS 190
TABLE 131 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 191
TABLE 132 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE
DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 191
TABLE 133 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 192
TABLE 134 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 192
TABLE 135 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 193
TABLE 136 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 194
TABLE 137 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION) 194
TABLE 138 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 195
TABLE 139 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 197
TABLE 140 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 197
TABLE 141 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 198
TABLE 142 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 198
TABLE 143 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 199
TABLE 144 CHINA: KEY MACROINDICATORS 200
TABLE 145 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 200
TABLE 146 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 201
TABLE 147 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 201
TABLE 148 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 202
TABLE 149 JAPAN: KEY MACROINDICATORS 202
TABLE 150 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 203
TABLE 151 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 203
TABLE 152 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 204
TABLE 153 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 204
TABLE 154 INDIA: KEY MACROINDICATORS 205
TABLE 155 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 206
TABLE 156 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 206
TABLE 157 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION,
2023–2030 (USD BILLION) 207
TABLE 158 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 207
TABLE 159 SOUTH KOREA: KEY MACROINDICATORS 208
TABLE 160 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 209
TABLE 161 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 209
TABLE 162 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 210
TABLE 163 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 210
TABLE 164 AUSTRALIA: KEY MACROINDICATORS 211
TABLE 165 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 212
TABLE 166 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 212
TABLE 167 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 213
TABLE 168 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 213
TABLE 169 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 214
TABLE 170 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 214
TABLE 171 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 215
TABLE 172 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 215
TABLE 173 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 216
TABLE 174 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 217
TABLE 175 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 217
TABLE 176 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 218
TABLE 177 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 218
TABLE 178 BRAZIL: KEY MACROINDICATORS 219
TABLE 179 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 219
TABLE 180 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 220
TABLE 181 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 220
TABLE 182 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 221
TABLE 183 MEXICO: KEY MACROINDICATORS 221
TABLE 184 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 222
TABLE 185 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 222
TABLE 186 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 223
TABLE 187 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 223
TABLE 188 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 224
TABLE 189 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 225
TABLE 190 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 225
TABLE 191 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 226
TABLE 192 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY REGION, 2023–2030 (USD BILLION) 227
TABLE 193 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 227
TABLE 194 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 228
TABLE 195 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 228
TABLE 196 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 229
TABLE 197 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 230
TABLE 198 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 230
TABLE 199 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 231
TABLE 200 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 231
TABLE 201 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 232
TABLE 202 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 233
TABLE 203 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 233
TABLE 204 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 234
TABLE 205 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 234
TABLE 206 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE,
2023–2030 (USD BILLION) 235
TABLE 207 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 236
TABLE 208 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2023–2030 (USD BILLION) 236
TABLE 209 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2023–2030 (USD BILLION) 237
TABLE 210 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD BILLION) 237
TABLE 211 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 238
TABLE 212 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY APPLICATION, 2023–2030 (USD BILLION) 238
TABLE 213 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET,
BY END USER, 2023–2030 (USD BILLION) 239
TABLE 214 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 239
TABLE 215 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE,
2023–2030 (USD BILLION) 240
TABLE 216 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 240
TABLE 217 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 241
TABLE 218 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET 242
TABLE 219 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOINJECTORS:
DEGREE OF COMPETITION 246
TABLE 220 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PEN INJECTORS:
DEGREE OF COMPETITION 247
TABLE 221 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES: DEGREE OF COMPETITION 248
TABLE 222 DRUG DEVICE COMBINATION PRODUCTS MARKET: REGION FOOTPRINT 254
TABLE 223 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT TYPE FOOTPRINT 255
TABLE 224 DRUG DEVICE COMBINATION PRODUCTS MARKET: APPLICATION FOOTPRINT 256
TABLE 225 DRUG DEVICE COMBINATION PRODUCTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 259
TABLE 226 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 259
TABLE 227 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 261
TABLE 228 DRUG DEVICE COMBINATION PRODUCTS MARKET:
DEALS, JANUARY 2022–MARCH 2025 262
TABLE 229 DRUG DEVICE COMBINATION PRODUCTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025 263
TABLE 230 DRUG DEVICE COMBINATION PRODUCTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 265
TABLE 231 ABBOTT: COMPANY OVERVIEW 266
TABLE 232 ABBOTT: PRODUCTS OFFERED 267
TABLE 233 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 268
TABLE 234 ABBOTT: DEALS, JANUARY 2022–MARCH 2025 269
TABLE 235 ELI LILLY AND COMPANY: COMPANY OVERVIEW 270
TABLE 236 ELI LILLY AND COMPANY: PRODUCTS OFFERED 271
TABLE 237 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 273
TABLE 238 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–MARCH 2025 274
TABLE 239 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025 275
TABLE 240 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 276
TABLE 241 MEDTRONIC: COMPANY OVERVIEW 278
TABLE 242 MEDTRONIC: PRODUCTS OFFERED 279
TABLE 243 MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–MARCH 2025 281
TABLE 244 MEDTRONIC: DEALS, JANUARY 2022–MARCH 2025 282
TABLE 245 NOVO NORDISK A/S: COMPANY OVERVIEW 284
TABLE 246 NOVO NORDISK A/S: PRODUCTS OFFERED 285
TABLE 247 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–MARCH 2025 286
TABLE 248 NOVO NORDISK A/S: DEALS, JANUARY 2022–MARCH 2025 287
TABLE 249 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–MARCH 2025 288
TABLE 250 NOVARTIS AG: COMPANY OVERVIEW 291
TABLE 251 NOVARTIS AG: PRODUCTS OFFERED 292
TABLE 252 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 294
TABLE 253 NOVARTIS AG: DEALS, JANUARY 2022–MARCH 2025 294
TABLE 254 NOVARTIS AG: EXPANSIONS, JANUARY 2022–MARCH 2025 295
TABLE 255 SANOFI: COMPANY OVERVIEW 297
TABLE 256 SANOFI: PRODUCTS OFFERED 298
TABLE 257 SANOFI: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 299
TABLE 258 SANOFI: DEALS, JANUARY 2022–MARCH 2025 300
TABLE 259 SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 301
TABLE 260 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 302
TABLE 261 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 303
TABLE 262 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS,
JANUARY 2022–MARCH 2025 305
TABLE 263 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–MARCH 2025 305
TABLE 264 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 306
TABLE 265 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 307
TABLE 266 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025 308
TABLE 267 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS,
JANUARY 2022–MARCH 2025 308
TABLE 268 MERCK KGAA: COMPANY OVERVIEW 309
TABLE 269 MERCK KGAA: PRODUCTS OFFERED 310
TABLE 270 MERCK KGGA: DEALS, JANUARY 2022–MARCH 2025 311
TABLE 271 ABBVIE INC.: COMPANY OVERVIEW 312
TABLE 272 ABBVIE INC.: PRODUCTS OFFERED 313
TABLE 273 ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 314
TABLE 274 ABBVIE INC.: DEALS, JANUARY 2022–MARCH 2025 315
TABLE 275 ABBVIE INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 315
TABLE 276 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 316
TABLE 277 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 317
TABLE 278 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS,
JANUARY 2022–MARCH 2025 318
TABLE 279 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS,
JANUARY 2022–MARCH 2025 318
TABLE 280 STRYKER: COMPANY OVERVIEW 319
TABLE 281 STRYKER: PRODUCTS OFFERED 320
TABLE 282 B. BRAUN SE: COMPANY OVERVIEW 321
TABLE 283 B. BRAUN SE: PRODUCTS OFFERED 322
TABLE 284 TERUMO CORPORATION: COMPANY OVERVIEW 323
TABLE 285 TERUMO CORPORATION: PRODUCTS OFFERED 324
TABLE 286 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–MARCH 2025 325
TABLE 287 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 326
TABLE 288 CEQUR SIMPLICITY: COMPANY OVERVIEW 326
TABLE 289 INTARCIA THERAPEUTICS, INC.: COMPANY OVERVIEW 327
TABLE 290 HALOZYME, INC.: COMPANY OVERVIEW 327
TABLE 291 KALEO, INC.: COMPANY OVERVIEW 328
TABLE 292 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW 329
TABLE 293 PURDUE PHARMA L.P.: COMPANY OVERVIEW 329
TABLE 294 ALVOGEN: COMPANY OVERVIEW 330
TABLE 295 EVOLUTIS: COMPANY OVERVIEW 330
TABLE 296 MUNDIPHARMA INTERNATIONAL LIMITED: COMPANY OVERVIEW 331
TABLE 297 SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY OVERVIEW 332
TABLE 298 SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 333
TABLE 299 ALCON INC.: COMPANY OVERVIEW 334
LIST OF FIGURES
FIGURE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 30
FIGURE 2 DRUG DEVICE COMBINATION PRODUCTS MARKET: YEARS CONSIDERED 31
FIGURE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: RESEARCH DESIGN 33
FIGURE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY DATA
FROM SECONDARY SOURCES 35
FIGURE 5 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PRIMARY SOURCES 36
FIGURE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: INSIGHTS FROM PRIMARIES 37
FIGURE 7 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARIES (BY COMPANY TYPE, DESIGNATION, AND REGION) 37
FIGURE 8 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 38
FIGURE 9 DRUG DEVICE COMBINATION PRODUCTS MARKET SIZE ESTIMATION:
SUPPLY-SIDE ANALYSIS (2024) 38
FIGURE 10 PEN INJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
(BOTTOM-UP APPROACH) 39
FIGURE 11 AUTOINJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
(BOTTOM-UP APPROACH) 40
FIGURE 12 DRUG DEVICE COMBINATION PRODUCTS MARKET: TOP-DOWN APPROACH 41
FIGURE 13 DRUG DEVICE COMBINATION PRODUCTS MARKET: CAGR PROJECTIONS
(SUPPLY SIDE) 42
FIGURE 14 DRUG DEVICE COMBINATION PRODUCTS MARKET: DATA TRIANGULATION 43
FIGURE 15 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE,
2025 VS. 2030 (USD BILLION) 46
FIGURE 16 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2025 VS. 2030 (USD BILLION) 47
FIGURE 17 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION,
2025 VS. 2030 (USD BILLION) 48
FIGURE 18 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER,
2025 VS. 2030 (USD BILLION) 49
FIGURE 19 REGIONAL SNAPSHOT OF DRUG DEVICE COMBINATION PRODUCTS MARKET 50
FIGURE 20 INCREASING NUMBER OF REGULATORY APPROVALS AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 51
FIGURE 21 CHINA AND DIABETES MANAGEMENT SEGMENT COMMANDED LARGEST MARKET SHARE IN 2024 52
FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 53
FIGURE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 24 DISABILITY-ADJUSTED LIFE YEARS FOR INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA, BY AGE (2023) 56
FIGURE 25 SHARE OF GLOBAL GERIATRIC POPULATION (ABOVE 60 YEARS), BY REGION,
2010 VS. 2015 VS. 2030 (PROJECTED) 57
FIGURE 26 DRUG DEVICE COMBINATION PRODUCTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 67
FIGURE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS 69
FIGURE 28 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS 70
FIGURE 29 DRUG DEVICE COMBINATION PRODUCTS MARKET: PATENT PUBLICATION TRENDS AND TOP APPLICANT ANALYSIS (JANUARY 2014–APRIL 2025) 80
FIGURE 30 TOP PATENT APPLICANTS FOR DRUG DEVICE COMBINATION PRODUCTS,
BY JURISDICTION (JANUARY 2014–APRIL 2025) 81
FIGURE 31 DRUG DEVICE COMBINATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS 89
FIGURE 32 DRUG DEVICE COMBINATION PRODUCTS MARKET: ADJACENT MARKETS 92
FIGURE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: ECOSYSTEM ANALYSIS 93
FIGURE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS 97
FIGURE 35 DRUG DEVICE COMBINATION PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
FIGURE 36 DRUG DEVICE COMBINATION PRODUCTS MARKET: FUNDING AND
NUMBER OF DEALS, 2019–2023 98
FIGURE 37 DRUG DEVICE COMBINATION PRODUCTS MARKET: IMPACT OF AI/GEN AI 103
FIGURE 38 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT 166
FIGURE 39 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT 196
FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DEVICE COMBINATION
PRODUCTS MARKET (2020–2024) 245
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET (2024) 246
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEN INJECTORS MARKET (2024) 247
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN TRANSDERMAL
PATCHES MARKET (2024) 248
FIGURE 44 RANKING OF KEY PLAYERS IN DRUG DEVICE COMBINATION
PRODUCTS MARKET (2024) 250
FIGURE 45 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 252
FIGURE 46 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY FOOTPRINT 253
FIGURE 47 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 258
FIGURE 48 EV/EBITDA OF KEY VENDORS 260
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 260
FIGURE 50 DRUG DEVICE COMBINATION PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 261
FIGURE 51 ABBOTT: COMPANY SNAPSHOT 267
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 271
FIGURE 53 MEDTRONIC: COMPANY SNAPSHOT 279
FIGURE 54 NOVO NORDISK A/S: COMPANY SNAPSHOT 285
FIGURE 55 NOVARTIS AG: COMPANY SNAPSHOT 292
FIGURE 56 SANOFI: COMPANY SNAPSHOT 298
FIGURE 57 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 303
FIGURE 58 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 307
FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT 310
FIGURE 60 ABBVIE INC.: COMPANY SNAPSHOT 313
FIGURE 61 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 316
FIGURE 62 STRYKER: COMPANY SNAPSHOT 320
FIGURE 63 B. BRAUN SE: COMPANY SNAPSHOT 322
FIGURE 64 TERUMO CORPORATION: COMPANY SNAPSHOT 324
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11